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Abstract
Multicriteria optimization methodology was applied in development of UHPLC-UV–MS method for
separation of cilazapril, hydrochlorothiazide and their degradation products. This method is also
applicable for analysis of cilazapril, hydrochlorothiazide and their degradation products in com-
bined tablet formulation. Prior to method optimization forced degradation studies were conducted.
Cilazapril and hydrochlorothiazide were subjected to acidic (0.1, 0.5 and 1.0M HCl), basic (0.1, 0.5
and 1.0M NaOH), thermal (70°C), oxidative (3–30% H2O2) degradation and photodegradation (day
light). Cilazapril appeared to be unstable toward acid and base and resulted in formation of cilaza-
prilat. Hydrochlorothiazide signiﬁcantly degraded after acid, base and thermal hydrolysis and
formed degradation product was 4-amino-6-chlorobenzene-1.3-disulfonamide. For both sub-
stances, after oxidative degradation unknown products have arisen. Initial percentage of aceto-
nitrile in mobile phase, ﬁnal percentage of acetonitrile in mobile phase, time of gradient elution
and column temperature were deﬁned as variables to be optimized toward two chromatographic
responses by means of central composite design and Derringer’s desirability function. The satis-
factory chromatographic analysis was achieved on Kinetex C18 (2.6 µm, 50 × 2.1mm) column with
temperature set at 25°C. The ﬁnal mobile phase consisted of acetonitrile and 20mM ammonium
formate buffer (pH adjusted to 8.5). The ﬂow rate of the mobile phase was 400 μLmin−1 and it was
pumped in a gradient elution mode.
Introduction
Hydrochlorothiazide (Figure 1A) is thiazide diuretic which is chem-
ically known as 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-
sulfonamide 1,1-dioxide. Its pharmacological effects include inhib-
ition of the sodium and chloride reabsorption from renal tubules
and enhancement of potassium secretion. Hydrochlorothiazide thus
increases secretion of sodium and water. It is used for treatment of
hypertension, edema associated with heart failure and kidney and
hepatic disorders. It is also used for treatment of edema followed
by premenstrual syndrome, treatment of diabetes insipidus, for
prevention of water retention caused by corticosteroids and preven-
tion of renal calculus formation in patients with hypercalciuria (1).
Cilazapril (Figure 1B) is angiotensin-converting enzyme which
is chemically known as (1S, 9S)-9-[[(1S)-1-(ethoxycarbonyl)-3-
phenylpropyl]amino]-10-oxooctahydro-6Hpyridazino[1,2-a] [1,2]
diazepine-1-carboxylic acid monohydrate. Cilazapril is pro drug of
cilazaprilat (diacid) which is also active metabolite. Cilazapril is
rapidly absorbed and metabolized in liver to more polar cilazaprilat.
Cilazapril is used for treatment of hypertension, heart failure and
myocardial infarction (1).
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com 625
D
ow
nloaded from
 https://academ
ic.oup.com
/chrom
sci/article-abstract/55/6/625/3073989 by Belgrade U
niversity user on 30 July 2019
Cilazapril and hydrochlorothiazide can be used as monotherapy,
but in combination they have synergistic antihypertensive effect which
results in a higher percentage of patients responding satisfactorily.
Fixed combinations of these two drugs with different mechanism are
used in order to apply minimal doses which will minimize clinical
and metabolic side effects (2). Forced degradation studies are comple-
mentary part of drug development strategy being undertaken for
identiﬁcation of degradation products, to elucidate the degradation
pathway and intrinsic stability of the drug. These studies are con-
ducted under more severe conditions then those used for accelerated
stability testing. Inﬂuence of environmental stress factors like pH,
temperature, humidity, oxygen and light are evaluated. Investigation
of degradation products formed under stress conditions is useful in
development and validation of suitable stability-indicating analytical
procedures and it is also necessary due to changes in toxicity, bio-
availability or therapeutic effects of the dosage form (3–5).
Experimental design as a chemometric tool represents the meth-
odology of planning and conducting experiments in order to gather
as much information as possible from minimal number of experi-
ments (6). The main aim of experimental design is examining inﬂu-
ence of every factor or method parameter as well as the possible
factor interactions and to optimize these factors after conducting
series of experiments. Central composite design (CCD) is response
surface design which is commonly used in optimization and robust-
ness assessment of analytical methods (7). CCD consists of full fac-
torial design and star design. The total number of experiments is
deﬁned by relation N = 2k + 2k + p, where k represents the number
of factors to be tested, p represents the replicates in central point.
Star points in the design are at the distance equal to +α or –α from
the experimental domain center, while the value α depends on
experiment criteria. Face centered CCD is created when the value of
α is set to 1. Repeats in central point serve for precise assessment of
pure experimental error, to stabilize variation of predicted response
and to measure the adequacy of the models (8–11).
When a single response is being analyzed, the model analysis
indicates the areas in the design region where the process is likely
to give desirable results, which is a relatively easy task. Local
optima corresponding to only one objective can be avoided by tak-
ing into account the whole spectra of objectives. The purpose of
multi-objective optimization (MOOP), also called multicriteria
decision-making approach, is to obtain optimality on the basis of
compromises among the various objectives. This methodology al-
lows the identiﬁcation of the best solution by optimizing several
dependent properties simultaneously. The advantage of MOOP
approach is creating a local optimal solution through a group of
different objectives which may contribute in a positive or a negative
way to the ﬁnal solution (12). Desirability functions are the most
widely used in this research area. This approach is based on the idea
that a quality of the process that has multiple quality characteristics,
with one of them outside of some “desired” limits, is completely
unacceptable. The method ﬁnds operating conditions x that provide
the “most desired” response values (13, 14).
The literature search revealed numerous methods for cilazapril
and hydrochlorothiazide determinations individually and in com-
bined pharmaceutical dosage forms. Various methods had been de-
scribed such as spectrophotometric (15–17), liquid chromatographic
(18–21) and capillary electrophorethic (22). Chromatographic meth-
ods with amperometric and photometric detection for rapid determi-
nations of cilazapril and cilazaprilat in urine were also reported
(23–26). RP-TLC determination of lipophilicity of cilazapril and hy-
drochlorothiazide was also described by using cellulose layers and
three linear solvent systems (27). Enzyme immunoassay had been
used for cilazapril determinations directly with serum or plasma
samples without pretreatment (28).
But to date, no information of stability-indicating method for ci-
lazapril and hydrochlorothiazide is available in the literature.
Concerning this, comprehensive UHPLC-UV–MS study of cilazapril
and hydrochlorothiazide degradation under stress conditions and
development and validation of UHPLC method has been reported.
Cilazapril, hydrochlorothiazide and their degradation products
showed different physical–chemical properties such as solubility, li-
pophilicity, absorption and polarity. Therefore, it was difﬁcult task
to conduct their simultaneous separation in one chromatographic
run. The novelty of this work includes the evaluation of cilazapril
and hydrochlorothiazide degradation pathway and chromatographic
behavior of two active substances and their degradation products
toward various variables in order to deﬁne the optimal chromato-
graphic conditions using experimental design and multiresponse
optimization methodology. These conditions enabled separation of
all compounds within the shortest possible analysis run time.
Materials and methods
Chemicals and reagents
The standard substances of cilazapril, hydrochlorothiazide, cilazaprilat
and impurity B of hydrochlorothiazide were obtained from Sigma-
Aldrich (Taufkirchen, Germany). Acetonitrile HPLC-gradient grade
was purchased from J.T. Baker (Deventer, the Netherlands). All other
used reagents were of analytical grade. Ammonium formate was pur-
chased from Sigma-Aldrich Chemie GmbH (Steinheim, Germany).
Ammonium hydroxide was obtained from Sigma-Aldrich Chemie
GmbH (Steinheim, Germany). Puriﬁed water was obtained using
Simplicity 185 Water puriﬁcation system, Millipore (Billerica,
Massachusetts, USA). Sodium hydroxide and hydrochloride acid were
purchased from Zorka Pharma (Šabac, Serbia), while 30% (v/v) hydro-
gen peroxide solution was purchased from Sigma-Aldrich Chemie
GmbH (Steinheim, Germany). The Prilazid plus® ﬁlm tablets contain-
ing 5mg of cilazapril and 12.5mg of hydrochlorothiazide (Galenika a.
d., Belgrade, Serbia) were purchased from a local drugstore. Syringe
driven ﬁlter units (LLG-nylon syringe ﬁlter 0.45 µm, LLG Labware,
Meckenheim, Germany) were used for sample solution ﬁltration.
Chromatographic conditions and equipment
Chromatographic analysis was performed on Thermo Scientiﬁc
UHPLC system (Thermo Fisher Scientiﬁc Inc., Waltham, USA)
Figure 1. Structures of hydrochlorothiazide (A), cilazapril (B), cilazaprilat (C)
and hydrochlorothiazide impurity B (D).
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which is equipped with Accela photodiode array (PDA) detector,
Accela auto sampler, Accela quaternary pump, column thermostat,
degasser and TSQ Quantum Access Max triple quadrupole mass
spectrometer. ChromQuest software, version 5.0 (Thermo Fisher
Scientiﬁc Inc., Waltham, USA) was used for data acquisition and
processing. Chromatographic separation was done by using Kinetex
C18 (2.6 µm, 50mm × 2.1mm) column (Phenomenex Inc.,
Torrance, USA). Electrospray ionization technique (ESI) was used
and data were acquired by means of Xcalibur version 1.3 software
(Thermo Fisher Scientiﬁc Inc., Waltham, USA). Tuning the mass
spectrometer by means of optimizing the ESI source and collision
cell was established in ESI-negative mode conditions with cilazapril
and hydrochlorothiazide solutions at concentration of 1 μgmL−1.
Both standard solutions were infused with the syringe pump at a
ﬂow rate of 5 µLmin−1 in mobile phase composition deﬁned as a
center point of CCD. The mass spectrometer operated in full scan
mode with mass to charge ratio (m/z) in the range of 100–2,000.
Spray needle voltage was set at 4,000 V. Nitrogen was used as a
sheath and auxiliary gas. Sheath gas pressure was 10 psi and auxil-
iary gas pressure was 55 psi. Vaporizer temperature was 354°C and
capillary temperature was 200°C. Argon was used as the collision
gas with a pressure of 2 mTorr.
Optimal chromatographic conditions included mobile phase
which consisted of acetonitrile (mobile phase A) and buffer solution
of 20mM ammonium formate (pH = 8.5) (mobile phase B). The
mobile phase was pumped at 400 μLmin−1 ﬂow rate in a gradient
elution mode: at 0minute 5% acetonitrile and 95% of buffer solu-
tion, at 15minute 35% acetonitrile and 65% buffer solution, at 16
minute 5% acetonitrile and 95% of buffer solution. The detection
performed using PDA detector was done at 250 nm. The chosen
temperature of the column was 25°C.
Design-Expert 7.0 software (Stat-Ease Inc., Minneapolis, USA)
was used in order to generate experimental design and to analyze
obtained responses. Marvin Sketch software (Chem Axon Ltd.,
Budapest, Hungary) was used to calculate the molecular descriptors,
log P and pKa values.
Experimental
Preparation of mobile phase, standard and sample
solutions
Standard stock solutions at concentrations of 1mgmL−1 for both ci-
lazapril and hydrochlorothiazide were prepared separately. Stock
solutions were prepared by dissolving 25mg of standard substances
in the mixture of acetonitrile–water (50:50, v/v) in 25mL volumetric
ﬂasks. The solutions were dissolved in the ultrasonic bath for 5
minutes and volumetric ﬂasks were ﬁlled to volume with mixture of
acetonitrile–water (50:50, v/v). Working concentration for both cila-
zapril and hydrochlorothiazide solutions was 100 μgmL−1. This
concentration was obtained after dilution of stock solutions with the
mixture of acetonitrile –20mM ammonium formate buffer solution
pH = 8.5 (20:80, v/v). Further dilution to concentration of 1 μg
mL−1 was achieved using the same mixture.
The 20mM ammonium formate buffer solution was prepared
and its pH value was adjusted to 8.5 with ammonium hydroxide.
Before the analysis, mobile phases (buffer solution and acetonitrile)
were ﬁltered by means of glass vacuum system Sartorius Stedim
Biotech (Göttingen, Germany) through nylon ﬁlter membrane 47mm
0.45 μm (Agilent Technologies, Santa Clara, USA). Mobile phase was
prepared freshly on the day required in the amounts that is sufﬁcient
for daily use. This ensured that the mobile phase stayed unchanged or
that buffer pH was unaffected by prolonged storage and that there
was no microbial growth that could affect chromatography.
Working standard solutions used for forced degradation studies
were prepared from stock solutions and contained cilazapril and hy-
drochlorothiazide in concentration of 100 μgmL−1, separately.
Working sample solution contained cilazapril and hydrochlorothia-
zide in concentrations of 100 and 250 μgmL−1, respectively. These
concentrations were obtained after mixing 1mL of stock solution
with 1mL of stress agent and ﬁlling to volume of 10mL with the
mixture of acetonitrile –20mM ammonium formate buffer pH =
8.5 (20:80, v/v) after appropriate time of stress testing. Acid
hydrolysis was performed by mixing 1mL of cilazapril or hydro-
chlorothiazide stock standard solutions separately in 10-mL volu-
metric ﬂasks with 1mL of 0.1, 0.5 and 1.0M HCl solution,
respectively. Alkaline hydrolysis was performed separately by mix-
ing 1mL of cilazapril or hydrochlorothiazide stock standard solu-
tions in 10-mL volumetric ﬂasks with 1mL of 0.1M, 0.5M and
1.0M NaOH, respectively. These mixtures were kept at room tem-
perature and at temperature of 70°C for 3 and prolonged to 6 hours
if no degradation was observed. Afterwards, the solutions were ﬁlled
to volume with mixture of acetonitrile –20mM ammonium formate
buffer solution pH = 8.5 (20:80, v/v). Oxidative forced degradation
study was performed by mixing 1mL of cilazapril or hydrochlor-
othiazide stock standard solutions separately in 10-mL volumetric
ﬂasks with 1mL of 3% (v/v), 10% (v/v) and 30% (v/v) H2O2 aque-
ous solutions, respectively. These mixtures were kept at room tem-
perature for 3 and 6 hours, respectively. Finally, volumetric ﬂasks
were ﬁlled to volume with mixture of acetonitrile –20mM ammo-
nium formate buffer solution pH = 8.5 (20:80, v/v). Thermal deg-
radation was examined with 1mL of stock sample solutions of
cilazapril or hydrochlorothiazide separately which was exposed to
70°C for 3 and 6 hours, respectively. Afterwards, the solutions were
ﬁlled to volume with mixture of acetonitrile –20mM ammonium
formate buffer solution pH = 8.5 (20:80, v/v). Photodegradation
was performed with 1mL of stock standard solutions of cilazapril
or hydrochlorothiazide separately which were exposed to the daily
sunlight for a period of 2 weeks, respectively. Afterwards, the solu-
tions were ﬁlled to volume with mixture of acetonitrile –20mM
ammonium formate buffer solution pH = 8.5 (20:80, v/v).
Photodegradation was investigated in the similar manner (time of
exposure to daily sunlight) with solid samples of both cilazapril and
hydrochlorothiazide which were used afterwards for preparation of
working solutions in the same concentrations as mentioned above.
The sample solution for analysis of cilazapril and hydrochlor-
othiazide in tablets was prepared from Prilazid plus® ﬁlm tablets.
The ﬁlm from those tablets was previously removed. The quantity of
20 tablets was accurately weighted, ﬁnely powdered and the amount
of powder equivalent to double average tablet mass was transferred
into 10mL volumetric ﬂask adding the mixture of acetonitrile–water
(50:50, v/v). The solution was dissolved in the ultrasonic bath for
20minutes and the mixture was ﬁlled to volume of 10mL with the
same solvent. The solution was ﬁltered through syringe driven ﬁlter
units 0.45 µm prior the injection. The obtained concentrations of ci-
lazapril and hydrochlorothiazide in this stock sample solution were
1 and 2.5mgmL−1, respectively.
Forced degradation studies of combined dosage form of cilaza-
pril and hydrochlorthiazide in tablets were performed in the same
way as forced degradation studies on standard substances by means
of harmonization of concentration levels, diluents and stress condi-
tions as previously described.
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During forced degradation studies, control samples were pre-
pared and used for proper interpretation of drug stability properties
for every stress condition. Besides, standard stock solutions of cila-
zapril and hydrochlorothiazide were kept in the dark and refriger-
ated during the whole study and the stress samples were prepared
freshly when needed for every investigated stress condition.
For method validation purposes, standard stock solutions of cila-
zapril and hydrochlorothiazide were prepared in concentrations of
1mgmL−1 and standard stock solutions of cilazaprilat and hydrochlor-
othiazide impurity B were prepared in concentrations 200 µgmL−1,
separately by dissolving standard substances in the mixture of aceto-
nitrile–water (50:50, v/v). Further dilutions of standard stock solu-
tions were done with the mixture of acetonitrile –20mM ammonium
formate buffer solution pH = 8.5 (20:80, v/v) in order to prepare
working solutions with concentrations in the following ranges:
44.00–132.00 µg mL−1 for cilazapril, 110.00–330.00 µgmL−1 for hy-
drochlorothiazide, 0.11–1.32 µgmL−1 for hydrochlorothiazide
impurity B and 0.044–0.528 µgmL−1 for cilazaprilat. The quantita-
tive analysis of cilazaprilat was done using methodology of standard
addition. Prior to completion to volume, cilazaprilat standard sub-
stance was added to investigated solutions. The stock sample solu-
tion prepared from Prilazid plus® ﬁlm tablets containing 1mgmL−1
of cilazapril and 2.5 mgmL−1 of hydrochlorothiazide, which prepar-
ation was described in relation to forced degradation studies was
also used for method validation purposes.
Stability of all standard solutions was inspected by comparison
of chromatograms of freshly prepared solutions with those that
were stored in refrigerator and/or on room temperature for 24
hours. No statistically signiﬁcant differences in obtained results indi-
cated that stability of standard solutions was not compromised.
Results
Forced degradation study
Forced degradation study included appropriate stress conditions in
accordance with the ICH regulatory guidelines (3). Various ap-
proaches were also found in the literature describing practical as-
pects of development of stability-indicating methods (5, 29–35).
For stability testing, cilazapril and hydrochlorothiazide were ex-
posed to stress conditions in solution state. Stress testing included
investigation of the thermal stability, acidic and alkaline hydrolytic
stability as well as stability toward oxidative agents. Control
samples were prepared for comparison with the stressed samples.
For every stress condition, it was necessary to prepare at least four
samples, which refers to the solution of active pharmaceutical ingre-
dient (API) stored under ambient conditions, blank solution contain-
ing stress agents, zero time sample containing the drug stored under
ambient conditions and analyzed immediately after preparation and
drug solution submitted to the stress conditions. Comparisons of
these results gave the proper assessment of changes.
The percentage of drug degradation was calculated as a ratio of
peak area of cilazapril and hydrochlorothiazide under ﬁnal stress
condition versus peak area of these substances in the solution
stored under ambient conditions from the chromatograms recorded
under optimal chromatographic conditions. The conﬁrmation of
peak identity in all stress samples was done with the assistance of
mass spectrometry. Mass spectra of standard substances and stress
samples were recorded in the negative ESI mode. Degradation pro-
ducts were identiﬁed based on their retention times and mass to
charge ratios (m/z) in mass spectrum. The obtained m/z value of
415.99 matched with that of cilazapril standard substance and m/z
value of 295.6 matched with that of hydrochlorothiazide standard
substance. Obtained percentage of degradation and obtained deg-
radation products of cilazapril and hydrochlorothiazide formed un-
der each stress condition were presented in Table I. The
representative chromatograms presented in Figures 2–5 enabled
insight into the composition of cilazapril and hydrochlorothiazide
stress solutions, respectively.
Chromatographic method development
Preliminary testing indicated which factors had inﬂuence on the chro-
matographic behavior of the investigated substances. Acetonitrile
was selected as organic modiﬁer because investigated substances
showed the best peak symmetry by using this solvent. Among buffers
compatible with mass spectrometer, ammonium formate was selected
and ammonium hydroxide was used for pH adjustment. It was
decided to work with 20mM ammonium formate buffer solution
which pH value was set at 8.5. Because of the differences in solubil-
ity, lipophilicity and polarity between investigated substances, it was
decided to use gradient elution mode in chromatographic method
development. Initial percentage of acetonitrile, ﬁnal percentage of
acetonitrile, time of gradient elution mode and temperature of the
column were optimized with the assistance of CCD. The domains
Table I. Stress Conditions, Obtained Degradation Products and Percentage of Degradation for Cilazapril and Hydrochlorothiazide
in Deﬁned Time of Exposure
Stress condition Time of exposure Mass balance (%) Degradation level (%) Degradation product
Cilazapril
Acid hydrolysis, 1.0M HCl 70°C 6 hours 98.43 10.04 Cilazaprilat
Base hydrolysis, 0.1M NaOH 30minutes 99.29 15.65 Cilazaprilat
Thermal degradation, 70°C 6 hours 100.00 No degradation
Oxidation, 15% (v/v) H2O2 15minutes 98.25 15.00 DPC1 (5.94%)
DPC2 (3.98%)
DPC3 (5.08%)
Photodegradation (day light) 2 weeks 99.50 No degradation
Hydrochlorothiazide
Acid hydrolysis, 1.0M HCl 70°C 1 hour 98.51 10.52 Hydrochlorothiazide impurity B (DPH1)
Base hydrolysis, 1.0M NaOH 70°C 3 hours 98.51 6.27 Hydrochlorothiazide impurity B (DPH1)
Thermal degradation, 70°C 3 hours 98.78 8.64 Hydrochlorothiazide impurity B (DPH1)
Oxidation, 30% (v/v) H2O2 3 hours 97.56 20.00 DPH2
Photodegradation (day light) 2 weeks 99.21 No degradation
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of investigated variables for CCD are presented in Table II, whereas
the plan of the performed experiments and corresponding responses
are presented in Table III. Experimental design included 30 experi-
ments varying four factors. All experiments were performed ran-
domly with six repeats in central point, in order to provide a
precise estimation of an experimental error, adequacy of the model
(lack of ﬁt) and the statistical signiﬁcance of inﬂuence of each
variable.
Investigated responses were retention factors of cilazapril and
hydrochlorothiazide degradation products, DPC3 and DPH1,
respectively, as the ﬁrst and the last eluting substances. Mathematical
model was built for each response. Design Expert 7.0.0. software
proposed presented response surface quadratic models for both
responses:
= − + − −
+ + + +
− − + −
− +
−
k x x x x
x x x x x x x x
x x x x x E x
x x
1.17 0.41 0.076 0.033 0.29
0.045 0.069 0.18 0.046
0.020 0.024 0.27 3.105
0.13 0.094
DPH 1 2 3 4
1 2 1 3 1 4 2 3
2 4 3 4 1
2 003
2
2
3
2
4
2
1
= − − + −
+ − − −
− − − +
− +
k x x x x
x x x x x x x x
x x x x x x
x x
36.17 2.51 6.43 3.59 0.92
0.013 0.48 0.12 0.91
0.090 0.43 0.28 1.55
0.30 0.058
DPC 1 2 3 4
1 2 1 3 1 4 2 3
2 4 3 4 1
2
2
2
3
2
4
2
3
Here, kDPH1 denotes the retention factor of DPH1 degradation
product, kDPC3 denotes retention factor of degradation product
Figure 2. The representative chromatograms of cilazapril acid degradation products with PDA detector (A) and mass spectrum (B), cilazapril base degradation
products with PDA detector (C) and mass spectrum (D, E).
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Figure 3. The representative chromatograms of cilazapril oxidative degradation products with PDA detector (A) and mass spectrum (B, C, D, E).
Figure 4. The representative chromatograms of hydrochlorothiazide acid degradation products with PDA detector (A) and mass spectrum (B), hydrochlorothiazide
base degradation products with PDA detector (C) and mass spectrum (D), mass spectrum of hydrochlorothiazide (E).
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DPC3 while variables x1, x2, x3 and x4 denote initial percentage of
acetonitrile, ﬁnal percentage of acetonitrile in the gradient elution
program, time of the gradient elution and temperature of the col-
umn, respectively.
The regression lack of ﬁt for mathematical models of both sub-
stances was determined performing F-test. F values were obtained
and then its corresponding P-values were calculated. If P-values
were above 0.05 it would indicate absence of lack of ﬁt and conse-
quently these models could be accepted as good predictive ones
(36). In our study, obtained P-values were PkDPH1 = 0.5445 and
PkDPC3 = 0.5830.
In order to achieve the best chromatographic performance of the
developed method, it was needed to select the experimental condi-
tions that enable the satisfactory retention for all investigated sub-
stances as well as to achieve this in the shortest possible time.
Therefore, two optimization goals were deﬁned (Table IV). The ﬁrst
goal included the maximization of the retention factor of DPH1 deg-
radation product in order to avoid its possible non-retention behav-
ior. The second goal was to minimize the retention factor of
degradation product DPC3 as the last eluting substance. As these
two goals were in contradiction, MOOP was done by means of
desirability functions. The mathematical models for both kDPH1 and
kDPC3 were used for calculation of predicted responses Yˆi and the
individual desirability functions di afterwards. Different desirability
functions can be used depending on whether the response has to be
maximized, minimized or assigned a target value. Desirability func-
tions proposed by Derringer and Suich were used in this study (37).
In case of the maximization of the response kDPH1, its individual
desirability function was deﬁned in the following equation:
⎧
⎨
⎪⎪
⎩
⎪⎪
⎡
⎣⎢
⎤
⎦⎥=
ˆ ≤
< ˆ <
ˆ ≥ =
( )ˆ −
−
d
Y L
L Y T
Y T U
0 if
if
1 if
1i
i i
Y L
T L
S
i i i
i i i
i i
i i
Figure 5. The representative chromatograms of hydrochlorothiazide oxidative degradation products with PDA detector (A) and mass spectrum (B), hydrochlor-
othiazide thermal degradation products with PDA detector (C) and mass spectrum (D).
Table II. Investigated Variables and their Domains Included in CCD
Variables Domains of
investigated variables
−1 0 +1
(A) Initial percentage of acetonitrile (%) 5 7.5 10
(B) Final percentage of acetonitrile (%) 25 30 35
(C) Time of gradient elution mode (minutes) 15 17.5 20
(D) Temperature of the column (°C) 25 32.5 40
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In this equation, Li, Ui and Ti were assigned to be the lower,
upper and target values, respectively, desired for the response Yˆi,
with Li ≤ Ti ≤ Ui. In this way, Ti was interpreted as a large enough
value for the response, which can be Ui.
In case of the minimization of the response kDPC3, the following
equation was used:
⎧
⎨
⎪⎪
⎩
⎪⎪
⎡
⎣⎢
⎤
⎦⎥=
ˆ ≤ =
< ˆ <
ˆ ≥
( )ˆ −
−
d
Y T L
U Y T
Y U
1 if
if
0 if
2i
i i i
Y U
T U
S
i i i
i i
i i
i i
Here, Ti denotes a small enough value for the response, which
can be Li.
The exponent s in both equations was used to determine how
important is to hit the target value Ti. For s = 1, the desirability
function would increase linearly toward Ti, larger s value would
indicate that it is very desirable that the value of Yˆi is close to Ti or
increase rapidly above Li and small values of s would indicate that
almost any value of Yˆi above Li and below Ui are acceptable or if
having values of Yˆi considerably above Li are not of critical import-
ance. In this study, the need to reach satisfactory retention factors of
all substances was the same and therefore the values of s exponent
was assigned to be one. The lower and upper bounds and deﬁned
goals used for construction of Derringer’s desirability function have
been presented in Table IV.
For each predicted response Yˆi, calculated desirability functions
di values were in the range between 0 and 1. The desirability func-
tion with di = 0 represented a completely undesirable value of Yˆi
and di = 1 represented a completely desirable response value.
The individual desirability functions were further combined
using the geometric mean in equation (3) with k denoting the num-
ber of responses. In such way, the overall desirability D was
estimated:
( )= ( )D d xd x xd.. 3r r kr k1 2 1k1 2
The values (rk) describing the importance for satisfying proposed
goals for individually responses were deﬁned to be the same for all
investigated responses and in this study, all rk values were assigned
to be 1. Value D gave the overall assessment of the desirability for
the combined response levels. It was noticed that the range of D va-
lues fell in the interval [0, 1] and increased as the balance of the
properties became more favorable. For any response di = 0, the
overall desirability was D = 0. Desirability maximum was located at
the levels of the independent variables that simultaneously produced
the maximum desirability.
Based on the optimization goals deﬁned in this study (Table IV),
the software Design-Expert 7.0.0 offered the global optimal condi-
tions. The proposed optimal values for all investigated variables
have been presented in Figure 6. Optimal chromatographic condi-
tions included initial percentage of acetonitrile to be 5%, ﬁnal per-
centage of acetonitrile 35%, time of gradient elution mode
15.38minutes during which percentage of acetonitrile would lin-
early grow and temperature of the column should be set to 25°C.
The level of satisfaction of each goal (individually desirability func-
tions) and both goals at the same time (over all desirability function)
has been presented in Figure 7. Further 3-D response surface of
overall desirability function has been presented in Figure 8.
Discussion
Forced degradation study
The intensity of stress agents and the duration of exposure periods
were chosen on the basis of total substance degradation. The speci-
ﬁed stress conditions were selected in order to obtain 5–20% deg-
radation of active substance (32). Degradation level below 5% was
considered as not signiﬁcant because very small amount of degrad-
ation products was generated and degradation proﬁle could not be
completely and reliably deﬁned. On the other hand, degradation
above 20% is useless since such high levels of degradation lead to
secondary and tertiary degradation product formation that might
not be observed under appropriate storage conditions and during
the shelf-life of dosage form (5, 36, 37).
The study on individual molecules was performed primarily in
order to be able to correctly interpret the drug degradation process
Table III. The Plan of the Experiments of CCD Design and
Investigated Responses
Experiment no. Variables Responses
A B C D kDPH1 kDPC3
1 −1 −1 1 1 1.027 50.138
2 −1 −1 −1 −1 2.416 41.722
3 1 −1 1 1 0.805 43.833
4 0 −1 0 0 0.944 44.502
5 0 0 1 0 1.166 40.000
6 0 0 0 0 1.300 36.123
7 1 −1 1 −1 0.944 46.250
8 0 0 0 0 0.900 35.900
9 0 0 0 −1 1.611 37.194
10 0 0 0 1 0.944 35.916
11 0 0 0 0 1.000 35.000
12 −1 0 0 0 1.694 38.611
13 1 −1 −1 1 0.888 36.250
14 1 1 −1 1 0.805 25.638
15 0 0 −1 0 0.944 32.388
16 1 1 1 −1 1.222 32.250
17 −1 1 −1 1 1.472 29.750
18 1 0 0 0 1.222 33.833
19 −1 1 1 1 1.342 34.868
20 −1 1 1 −1 2.250 37.888
21 0 0 0 0 1.277 36.583
22 0 1 0 0 1.416 31.583
23 −1 −1 1 −1 2.222 51.972
24 −1 −1 −1 1 1.611 40.638
25 1 1 1 1 1.000 28.472
26 0 0 0 0 1.300 35.400
27 1 −1 −1 −1 0.861 37.805
28 0 0 0 0 1.127 36.000
29 1 1 −1 −1 1.277 26.472
30 −1 1 −1 −1 2.305 30.444
Table IV. Set Criteria for Construction of Derringer’s Desirability
Function of Investigated Responses
Response Goal Lower limit Upper limit
kDPH1 In range 2.40 2.50
kDPC3 To minimize 25.64 51.97
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and evaluate the impact of drug formulation and the presence of
two drugs in the mixture. Consistence of the MS spectra recorded
by the mass spectrometric detector and the UV absorption spectra
recorded by the photodiode array detector that had been monitored
through the whole forced degradation study, enabled the clear un-
derstanding of the sum result of degradation processes in all investi-
gated stress samples. Mass balance values calculated using data
from chromatograms of each stress sample were very close to 100%
in all cases (Table I), which proved that there were no undetected
peaks or degradation products that have not been taken under
consideration.
Firstly, the degradation of cilazapril will be discussed. As could
be seen from the Table I, under the inﬂuence of 1.0M HCl at 70°C
in 6 hours cilazapril had been degraded in amount of 10.04%. The
inﬂuence of 0.1M HCl at room temperature was ﬁrstly investigated
and degradation of cilazapril was beyond 5%. To induce degrad-
ation of the substance the strength of the acid was increased to
0.5M and then to 1.0M HCl. Still the degradation was not above
5% after 3 days. For this reason, the temperature was raised to
70°C and after 6 hours the degradation of 10.04% was achieved.
The degradation process resulted in formation of cilazaprilat which
appeared to be the only degradation product (Figure 1C). This result
was in accordance with theoretical knowledge since cilazapril chem-
ically represents an ester and it was expected to hydrolyze under the
inﬂuence of the acid and largely hydrolyze under the inﬂuence of
base. The representative chromatograms of acid degradation have
been presented in Figure 2A and B. Figure 2A presents the chro-
matogram obtained with PDA detector set at 250 nm. Only one
peak of degradation product has been noticed at retention time of
1.08min. To identify this peak, the mass spectrum was obtained at
this retention time and it was conﬁrmed that the m/z value of this
degradation product was 387.79 (Figure 2B). This m/z value corre-
sponds to cilazaprilat as it was expected.
Further, under the inﬂuence of 0.1M NaOH at room tempera-
ture in 30minutes cilazapril had been degraded in amount of
15.65%. This was expected as described above. The representative
chromatograms have been presented in Figure 2C–E. PDA chro-
matogram obtained at 250 nm has been presented in Figure 2C.
Two peaks of degradation products have been noticed. One peak
has retention time of 2.34minutes and the other has been noticed at
8.01minutes. Using mass spectrometer, it was conﬁrmed that peak
at 2.34minutes corresponded to cilazaprilat. Mass spectrum ob-
tained at this retention time and only m/z value was 388.0 which
correspond to cilazaprilat has been presented in Figure 2D. In
Figure 2E, it could be seen that all m/z values correspond to back-
ground and this peak was the consequent of gradient ﬂow of the
mobile phase. It could be concluded that degradation of cilazapril
under basic conditions resulted in formation of one degradation
product and this degradation product was identiﬁed as cilazaprilat.
It was noticed that the same degradation product appeared at two
different retention times. This was the consequence of the differences
in pH values that existed in investigated samples since 1.0M HCl
was added in one sample and 0.1M NaOH in the other.
Next step in the investigation was to obtain data concerning oxi-
dative degradation of the drug. The drug was exposed to H2O2 as
Figure 6. Graphically presented ramps of the optimal chromatographic conditions on global chromatographic optimum.
Figure 7. Representative Pareto chart of level of desirability for individual
and overall desirability function.
Figure 8. Response surface plot of global desirability function D for the
optimization of initial % ACN and ﬁnal % CAN.
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oxidative agent. After exposure to 30% (v/v) H2O2 solution the deg-
radation was above 20% and the exposure was repeated with 15%
H2O2. After 15minutes, the achieved degradation was 15.00% and
obtained degradation products have been presented in Figure 3A–
E. PDA chromatogram and three degradation products can be no-
ticed at retention times 7.03, 10.51 and 10.77minutes in Figure 3A.
Mass spectrum of ﬁrst degradation product which retention time
was 7.03minutes has been presented in Figure 3B. The m/z which
corresponds to this degradation product is 429.75. One more peak
at retention time 7.75minutes was observed (Figure 3A) but this
peak was conﬁrmed to be the background noise (Figure 3C).
Further in Figure 3D, it could be noticed that m/z value that corre-
sponds to degradation product which retention time is 10.51
minutes is 431.89 and the last degradation product at 10.77minutes
has m/z 430.83 (Figure 3E). It could be concluded that three differ-
ent degradation products have been formed under the inﬂuence of
oxidation agent. These degradation products were denoted as DPC1
(7.03minutes), DPC2 (10.51minutes) and DPC3 (10.77minutes).
The changes in cilazapril molecule due to oxidation could be pro-
posed according to the m/z values and fragmentation pattern ob-
tained from LC–MS-MS analyses, but further elucidation of
chemical structures of degradation products is planned for future
investigation.
Cilazapril showed to be stable to high temperature since no deg-
radation was observed after exposure to 70°C for 6 hours.
Cilazapril showed to be stable toward photodegradation since no
signiﬁcant degradation was observed after exposure to the daily sun-
light for a period of 2 weeks. The same results were observed in the
experiments with cilazapril solid substance exposed to daily light as
well as with cilazapril in solution state.
Secondly, the degradation of hydrochlorothiazide will be dis-
cussed. It could be seen from the data in Table I that hydrochlor-
othiazide appeared to be unstable under all investigated conditions,
except photodegradation. The addition of 1.0M HCl at 70°C in
1 hour resulted in 10.52% degradation of active pharmaceutical
substance. The inﬂuence of 0.1M, 0.5M and 1.0M HCl at room
temperature resulted in no degradation and consequently it was
decided to increase temperature to 70°C. The degradation resulted
in formation of one degradation product eluting at 1.09minutes as
can be seen in Figure 4A. The identity of the peak was conﬁrmed
with mass spectrum presented in Figure 4B. This degradation prod-
uct has the m/z 283.78 which matched with m/z value of the known
hydrochlorothiazide impurity B (Figure 1D) listed in the European
Pharmacopoeia (38). It was expected from available literature and
conﬁrmed under these experimental conditions that hydrochlor-
othiazide will degrade to hydrochlorothiazide impurity B (39). This
impurity was further denoted as DPH1. The peak seen at 7.81 was
conﬁrmed to be the background noise.
Under the inﬂuence of 1.0M NaOH at room temperature no
degradation was observed for 3 days. For this reason, the tempera-
ture was increased to 70°C and in 3 hours degradation was in-
creased to 6.27%. One degradation product was noticed eluting at
0.78minutes (Figure 4C). This degradation product was also identi-
ﬁed as DPH1 (Figure 4D). Difference in retention times of DPH1
in both samples was due to different pH values in these samples.
In one 1.0M HCl was added and in another 1.0M NaOH. Also,
the difference in retention times of hydrochlorothiazide after acid
and base hydrolysis could be noticed. The identity of the drug was
conﬁrmed using mass spectra and it could be seen in Figure 4E
where m/z value of 295.7 conﬁrmed that both peaks belonged to
hydrochlorothiazide.
Next step in the investigation was to obtain data concerning oxi-
dative degradation of the drug. The drug was exposed to H2O2 as
oxidative agent. After exposure of the drug to 30% (v/v) H2O2 solu-
tion in 3 hours, it resulted in the degradation of 20.00%. Inﬂuence
of oxidative agent resulted in formation of one degradation
product. It could be seen in Figure 5A that retention time of this
degradation product was 2.04 and its m/z value was 311.5
(Figure 5B). The identity of this degradation product is not known
and it was denoted as DPH2.
Sensitivity of hydrochlorothiazide to thermal degradation was in-
vestigated. The drug degraded 8.64% in 3 hours and the degrad-
ation resulted in formation of one degradation product (Figure 5C).
The obtained degradation product was identiﬁed as DPH1
(Figure 5D). The exposure of hydrochlorothiazide solid substance
and in solution state to daily sunlight for a period of 2 weeks did
not lead to any signiﬁcant degradation. Therefore, it was concluded
that the drug is stable toward photodegradation.
Experiments that involved combination dosage form of cilazapril
and hydrochlorothiazide in tablets were performed in order to prove
the applicability of the method to the real time situations and to
asses if excipients of the formulation could demonstrate additional
impact on the formation of degradation products. After these experi-
ments, it was conﬁrmed that the same degradation processes could
be noticed as for individual molecules.
Chromatographic method development and validation
Prior to experiments, log P and pKa values were calculated for both
cilazapril and hydrochlorothiazide. The log P for cilazapril was 1.95
and for hydrochlorothiazide log P was 0.16. These different values
obviously indicated the presence of high differences in polarities
between these substances. This was conﬁrmed experimentally as
much higher percentage of acetonitrile was needed for elution of ci-
lazapril comparing to hydrochlorothiazide. It was not possible to
select the appropriate amount of acetonitrile for isocratic elution of
both substances in a reasonable run time. For this reason, it was
decided to use gradient elution mode. Further, pKa values and pH
dependence of ionic and non-ionic forms plotted for both substances
indicated that cilazapril exists in anionic form when pH value
of drug solution is in the range between 3 and 6, and in di-
anionic form when pH value is above 6. On the other hand, hydro-
chlorothiazide exists in molecular form when pH value of the solu-
tion is equal or lower than 8.5.
It was further decided to work with 20mM ammonium formate
buffer solution with pH value set at 8.5. This decision was made
based on the peak symmetries of investigated substances. Among
both substances, hydrochlorothiazide had a peak tailing which jeo-
pardized its integration. This problem was solved with mobile phase
composition consisted of acetonitrile and 20mM ammonium for-
mate buffer solution whose pH was adjusted to 8.5.
Photodiode array detector is being used during forced degrad-
ation studies because of its ability to perform simultaneous detec-
tion of analyte on different wavelengths in order to have insight in
the formation of degradation products with different absorption
properties in comparison to parent drug. In this study, UV spectra
of cilazapril and hydrochlorothiazide and of all their degradation
products were recorded in order to differentiate them by their spec-
tral characteristics. After the analysis of absorption spectra, it was
concluded that all compounds could be detected on three wave-
lengths used for detection of stress samples (215, 250 and 270 nm).
Finally, during stability-indicating method development, it was
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decided to perform detection on single wavelength of 250 nm
because all compounds showed to have good absorption on this
wavelength (40–42).
Peak purity calculations that photodiode array detector provides,
were done in order to ensure the “purity” of the chromatographic
peak, the absence of co-elution and in such way to prove the select-
ivity of the method. Peak purity index which was greater than 990
conﬁrmed homogenous and pure peaks of cilazapril, hydrochlor-
othiazide and their degradation products in all analysed samples.
Consistence of the MS spectra recorded by the mass spectrometric
detector that had been monitored through the whole forced degrad-
ation study also proved the absence of co-elution.
DPH1 was the ﬁrst eluting substance and the most polar one.
Consequently, this impurity showed non-retention behavior for
most of experimental conditions. For this reason, one of the opti-
mization goals was retention factor of DPH1 to be >2. Only in this
way it could be expected to have satisfactory retention behavior and
good separation of this compound from the peak of the mobile
phase. Besides this goal, it was also needed to optimize method in
order to avoid unnecessarily long chromatographic run time. For
this reason, second optimization goal was to minimize the retention
time of the last eluting compound (DPC3). As these two goals were
in contradiction, it was necessary to ﬁnd the best compromise
between them. It also has to be noted that in case that DPH1 had
retention factor above 2, no resolution between neighboring peaks
was jeopardized and there was no need for implementation of any
additional optimization goals.
After conducting the experiments according to the CCD experi-
mental plan the obtained data was processed with the assistance of
the Design-Expert 7.0.0 software. The software indicated that global
optimal conditions may include initial percentage of acetonitrile set at
5%, ﬁnal percentage of acetonitrile 35%, time of gradient elution
mode of 15.38minutes during which percentage of acetonitrile would
linearly grow and temperature of the column to be set at 25°C. This
experimental conditions have completely satisﬁed ﬁrst goal of MOOP
concerning (kDPH1) and obtained individual desirability function had
maximal value ( =d 1i DPH1 ). But, in case of the second response,
(kDPC3), the optimization goal was not completely satisﬁed since the
individual desirability function was =d 0.787i DPC2 . Based on the fact
that these chromatographic conditions enabled satisfactory retention
of the ﬁrst compound and as lowest possible chromatographic run
time, these results were accepted as the optimal ones. Graphically pre-
sented ramps of the optimal chromatographic conditions and lower
and upper bounds have been presented in Figure 6 and the level of
desirability for individual and overall desirability functions has been
presented in Figure 7.
The response surface plot of global desirability function
= ( )D f initial% ACN, final% ACN when temperature of the col-
umn was set at 25°C and time of gradient elution was 15.38minutes
have been presented in Figure 8. The highest value of global desir-
ability function was obtained with lowest percentage of acetonitrile
in initial step and with the highest percentage of acetonitrile at the
end point of the gradient elution. But the response surface indicated
that the proposed optimal conditions would not contrive a robust
method. Small changes of experimental conditions would lead to
drastic changes of global function and consequently of investigated
responses. These facts were not of further consideration as the satis-
factory retention would be obtained with small changes and the ini-
tial and ﬁnal percentage of acetonitrile are mechanically controlled
and could not be changed in such extent to inﬂuence the chromato-
graphic method. Because of this, the proposed experimental condi-
tions were selected as the optimal ones. Beside all previous
discussion of the inﬂuence of chromatographic parameters on reten-
tion factors of all investigated substances described in relation to
chromatographic method development, some of instrumental para-
meters usually involved in method robustness testing were also con-
sidered. It was concluded that the change of detection wavelength in
the range of ±2 nm or mobile phase ﬂow rate in the range of
±0.1mL min−1 did not signiﬁcantly alter the chromatographic
behavior of investigated substances.
The system suitability parameters determined by analyzing the
chromatograms recorded on optimal chromatographic conditions
have been presented in Table V.
The developed method was subjected to ﬁnal method validation
as per ICH guidelines (43). The validation procedure was performed
for both active substances and for two known impurities described
in European pharmacopoeia (38), cilazaprilat and hydrochlorothia-
zide impurity B. Limits of detection and quantiﬁcation (LOQ) were
determined experimentally for impurities. Linear least squares
regression was applied and reported correlation coefﬁcients indi-
cated acceptable linearity of all calibration curves since they were
greater than 0.99 and 0.98 in cases of APIs and impurities, respect-
ively (44). Intra-assay precision was demonstrated for six replicate
analyses of sample solutions prepared in order to attain concentra-
tions of 88mgmL−1 for cilazapril and 220mgmL−1 for hydrochlor-
othiazide. Since the range of measured areas of cilazaprilat
chromatographic peaks used for construction of calibration curve
was very narrow, the methodology of standard addition was used
for its quantiﬁcation (45). In such was proper estimation of its
amount and reliable measurements were enabled. Obtained values
of relative standard deviations (RSD) met the acceptance criteria. In
case of API, RSD should not exceed 2% and in case of impurities
Table V. System Suitability Parameters of the Developed Method
System suitability
parameter
Retention time
(min)
Relative retention
timea
Resolution factor, Rs Number of theoretical
plates
Asymmetry
factor
Cilazapril 10.84 1 Rs DPC1/Cilazapril = 13.58 3,881 1.08
Cilazaprilat 3.62 0.34 Rs Cilazaprilat/DPH2 = 4.26 3,719 1.11
DPC1 7.92 0.73 Rs Cilazaprilat/DPC1 = 11.94 3,976 1.07
DPC2 11.22 1.04 Rs DPC2/Cilazapril = 1.95 3,766 1.15
DPC3 11.39 1.05 Rs DPC2/DPC3 = 1.36 3,253 1.18
Hydrochlorothiazide 1.81 1 3,590 1.12
DPH1 1.37 0.76 Rs Hydrochlorothiazide/DPH1 = 1.32 4,119 1.13
DPH2 2.15 1.19 Rs Hydrochlorothiazide/DPH2 = 1.62 3,285 1.16
aMeasured in relation to the retention time of appropriate parent drug.
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present in maximum allowed content (MAC) between 0.5 and 1.0%
RSD should not exceed 10% (44). The Recovery values obtained for
the method accuracy investigations were within ±2% for both APIs
and within ±10% for impurities (44). Results of method validation
have been summarized in Table VI.
Conclusion
CCD and Derringer’s desirability function were applied for opti-
mization of chromatographic variables toward various responses in
order to deﬁne stability-indicating UHPLC-UV–MS method for
determination of cilazapril, hydrochlorothiazide and its degradation
products. Forced degradation studies were carried out in order to
assess which degradation products of cilazapril and hydrochlor-
othiazide should be involved in development of proposed method.
The main advantage of this method is evaluation of chromato-
graphic behavior of cilazapril, hydrochlorothiazide and their deg-
radation products.
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